MX2019014697A - Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. - Google Patents
Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.Info
- Publication number
- MX2019014697A MX2019014697A MX2019014697A MX2019014697A MX2019014697A MX 2019014697 A MX2019014697 A MX 2019014697A MX 2019014697 A MX2019014697 A MX 2019014697A MX 2019014697 A MX2019014697 A MX 2019014697A MX 2019014697 A MX2019014697 A MX 2019014697A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- rage
- treatment
- phosphomimetic
- dna damage
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000033616 DNA repair Effects 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiera a una proteína RAGE fosfomimética que comprende una secuencia de aminoácido que es al menos 90% idéntica a una isoforma RAGE de mamífero nativa o uno de sus fragmentos en donde al menos una serina presente en la cola citoplasmática de la isoforma RAGE de mamífero es reemplazada por una estructura fosfomimética. La invención además se refiere a un polinucleótido que codifica la proteína RAGE fosfomimética y un vector que comprende el polinucleótido. Finalmente, la invención relates a una composición que comprende un portador y un ingrediente farmacéutico activo, seleccionado de la proteína RAGE, el vector para usarse en el tratamiento o prevención de una enfermedad en un paciente, en donde la enfermedad preferiblemente se selecciona de una enfermedad que inicia por una reparación deficiente del ADN, una enfermedad que inicia por un daño de ADN aumentado o una enfermedad que inicia por la senescencia aumentada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17177679.2A EP3418298A1 (en) | 2017-06-23 | 2017-06-23 | Rage proteins for the treatment of fibrosis and dna damage mediated diseases |
| PCT/EP2018/066794 WO2018234555A1 (en) | 2017-06-23 | 2018-06-22 | Rage proteins for the treatment of fibrosis and dna damage mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014697A true MX2019014697A (es) | 2020-08-03 |
Family
ID=59284983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014697A MX2019014697A (es) | 2017-06-23 | 2018-06-22 | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200140518A1 (es) |
| EP (2) | EP3418298A1 (es) |
| CN (1) | CN110785430A (es) |
| MX (1) | MX2019014697A (es) |
| WO (1) | WO2018234555A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230374087A1 (en) * | 2020-09-23 | 2023-11-23 | The Johns Hopkins University | Method to improve protein quality control |
| CN116251171A (zh) * | 2021-12-10 | 2023-06-13 | 南京景瑞康分子医药科技有限公司 | 可溶性晚期糖基化终末产物受体蛋白用于预防或治疗肺部感染疾病的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009108274A2 (en) * | 2008-02-26 | 2009-09-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
| KR20110139292A (ko) * | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
-
2017
- 2017-06-23 EP EP17177679.2A patent/EP3418298A1/en not_active Withdrawn
-
2018
- 2018-06-22 CN CN201880042077.1A patent/CN110785430A/zh active Pending
- 2018-06-22 EP EP18736828.7A patent/EP3642223A1/en not_active Withdrawn
- 2018-06-22 US US16/625,212 patent/US20200140518A1/en not_active Abandoned
- 2018-06-22 MX MX2019014697A patent/MX2019014697A/es unknown
- 2018-06-22 WO PCT/EP2018/066794 patent/WO2018234555A1/en not_active Ceased
-
2023
- 2023-08-16 US US18/450,524 patent/US20240025960A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3642223A1 (en) | 2020-04-29 |
| CN110785430A (zh) | 2020-02-11 |
| US20200140518A1 (en) | 2020-05-07 |
| EP3418298A1 (en) | 2018-12-26 |
| WO2018234555A1 (en) | 2018-12-27 |
| US20240025960A1 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| MX2021015753A (es) | Constructo de arn. | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| EA201792047A1 (ru) | Новые соединения | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| WO2017053732A3 (en) | Composition and method for treating complement-mediated disease | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| PE20150923A1 (es) | Moleculas de union il-17a novedosas y usos medicos de las mismas | |
| MX2020011333A (es) | Uso terapeutico de proteinas morfogeneticas oseas. | |
| EA201892493A1 (ru) | Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином | |
| MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| WO2019036725A3 (en) | PEPTIDE INHIBITORS OF TAU AGGREGATION | |
| BR112016023519A2 (pt) | inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| WO2016205397A3 (en) | Target-specific delivery of therapeutic agents | |
| MX2024009890A (es) | Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas |